Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
Allied Critical Metals Closes Final Tranche of Over-Subscribed Non-Brokered Private Placement Upsized to $5.1 Million
